Department of Cardiology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
J Interv Card Electrophysiol. 2021 Oct;62(1):199-211. doi: 10.1007/s10840-020-00878-9. Epub 2020 Oct 4.
Point-by-point radiofrequency (RF) ablation has been the cornerstone of pulmonary vein isolation (PVI) for patients with atrial fibrillation (AF); however, it remains a complex and time-consuming procedure. Many novel AF catheter ablation (CA) techniques have been introduced, but whether they represent valuable alternatives remains controversial. Thus, we conducted a network meta-analysis to comprehensively evaluate the efficacy and safety of different CA interventions.
We systematically searched several databases (Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov ) from inception to March, 2020. The primary outcomes of interest were freedom from atrial tachyarrhythmia (AT) and procedure-related complications; secondary outcomes included procedure time and fluoroscopy time.
Finally, 33 randomized controlled trials (RCTs) with a total of 4801 patients were enrolled. No significant differences were found among the different interventions in terms of primary efficacy or safety outcomes. PVAC was most likely to have the shortest procedure time (Prbest = 61.5%) and nMARQ the shortest fluoroscopy time (Prbest = 60.6%); compared with conventional irrigated RF (IRF) ablation, cryoballoon ablation (CBA) showed comparable clinical efficacy and safety; CBA with second-generation CB (CB2) had a significantly shorter procedure time than IRF with contact force technology (CF-IRF) (WMD = - 20.75; p = 0.00).
There is insufficient evidence to suggest that one CA technique is superior to another. However, PVAC may be associated with a shorter procedural duration, and the CB2 catheters also seemed to reduce the procedure time compared with that of CF-IRF. Further large-scale studies are warranted to compare the available CA techniques and provide an up-to-date optimum recommendation.
点式射频(RF)消融已成为心房颤动(AF)患者肺静脉隔离(PVI)的基石;然而,它仍然是一个复杂且耗时的过程。许多新型房颤导管消融(CA)技术已经引入,但它们是否代表有价值的替代方法仍存在争议。因此,我们进行了一项网络荟萃分析,以全面评估不同 CA 干预措施的疗效和安全性。
我们从开始到 2020 年 3 月系统地搜索了几个数据库(Embase、PubMed、Cochrane 图书馆和 ClinicalTrials.gov)。主要观察终点是无房性心动过速(AT)和与程序相关的并发症;次要观察终点包括手术时间和透视时间。
最终纳入了 33 项随机对照试验(RCT),共 4801 例患者。不同干预措施在主要疗效或安全性结局方面没有显著差异。PVAC 最有可能具有最短的手术时间(Prbest=61.5%)和 nMARQ 最短的透视时间(Prbest=60.6%);与常规灌流射频(IRF)消融相比,冷冻球囊消融(CBA)具有相似的临床疗效和安全性;与接触力技术(CF-IRF)相比,第二代 CB(CB2)的 CBA 具有明显更短的手术时间(WMD=-20.75;p=0.00)。
没有足够的证据表明一种 CA 技术优于另一种。然而,PVAC 可能与较短的手术时间有关,并且与 CF-IRF 相比,CB2 导管似乎也可以缩短手术时间。需要进一步进行大规模研究来比较现有的 CA 技术,并提供最新的最佳建议。